Literature DB >> 30504872

Efficient scarless genome editing in human pluripotent stem cells.

Kazuya Ikeda1, Nobuko Uchida2, Toshinobu Nishimura3, Joseph White4, Renata M Martin1, Hiromitsu Nakauchi3, Vittorio Sebastiano4, Kenneth I Weinberg1, Matthew H Porteus5.   

Abstract

Scarless genome editing in human pluripotent stem cells (hPSCs) represents a goal for both precise research applications and clinical translation of hPSC-derived therapies. Here we established a versatile and efficient method that combines CRISPR-Cas9-mediated homologous recombination with positive-negative selection of edited clones to generate scarless genetic changes in hPSCs.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30504872     DOI： 10.1038/s41592-018-0212-y

Source DB:  PubMed          Journal:  Nat Methods        ISSN： 1548-7091            Impact factor:   28.547


  10 in total

1.  Cas9-induced large deletions and small indels are controlled in a convergent fashion.

Authors:  Michael Kosicki; Felicity Allen; Frances Steward; Kärt Tomberg; Yangyang Pan; Allan Bradley
Journal:  Nat Commun       Date:  2022-06-14       Impact factor: 17.694

2.  Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.

Authors:  Mitchell L Leibowitz; Stamatis Papathanasiou; Phillip A Doerfler; Logan J Blaine; Lili Sun; Yu Yao; Cheng-Zhong Zhang; Mitchell J Weiss; David Pellman
Journal:  Nat Genet       Date:  2021-04-12       Impact factor: 38.330

3.  Efficient gene editing through an intronic selection marker in cells.

Authors:  Shang Wang; Yuqing Li; Li Zhong; Kai Wu; Ruhua Zhang; Tiebang Kang; Song Wu; Yuanzhong Wu
Journal:  Cell Mol Life Sci       Date:  2022-01-31       Impact factor: 9.261

4.  CRISPR Del/Rei: a simple, flexible, and efficient pipeline for scarless genome editing.

Authors:  Kyra L Feuer; Marah H Wahbeh; Christian Yovo; Eman Rabie; Anh-Thu N Lam; Sara Abdollahi; Lindsay J Young; Bailey Rike; Akul Umamageswaran; Dimitrios Avramopoulos
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

5.  Biallelic and gene-wide genomic substitution for endogenous intron and retroelement mutagenesis in human cells.

Authors:  Tomoyuki Ohno; Taichi Akase; Shunya Kono; Hikaru Kurasawa; Takuto Takashima; Shinya Kaneko; Yasunori Aizawa
Journal:  Nat Commun       Date:  2022-07-21       Impact factor: 17.694

Review 6.  Selecting for CRISPR-Edited Knock-In Cells.

Authors:  Nina Reuven; Yosef Shaul
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

Review 7.  Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.

Authors:  Yoshiki Furukawa; Yasuharu Hamano; Shuichi Shirane; Shintaro Kinoshita; Yoko Azusawa; Jun Ando; Hiromitsu Nakauchi; Miki Ando
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

8.  Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.

Authors:  Dina Simkin; Vasileios Papakis; Bernabe I Bustos; Christina M Ambrosi; Steven J Ryan; Valeriya Baru; Luis A Williams; Graham T Dempsey; Owen B McManus; John E Landers; Steven J Lubbe; Alfred L George; Evangelos Kiskinis
Journal:  Stem Cell Reports       Date:  2022-03-10       Impact factor: 7.294

9.  Generation of human striatal organoids and cortico-striatal assembloids from human pluripotent stem cells.

Authors:  Yuki Miura; Min-Yin Li; Fikri Birey; Kazuya Ikeda; Omer Revah; Mayuri Vijay Thete; Jin-Young Park; Alyssa Puno; Samuel H Lee; Matthew H Porteus; Sergiu P Pașca
Journal:  Nat Biotechnol       Date:  2020-12-03       Impact factor: 68.164

10.  A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy.

Authors:  Neha R Dhoke; Hyunkee Kim; Sridhar Selvaraj; Karim Azzag; Haowen Zhou; Nelio A J Oliveira; Sudheer Tungtur; Carolina Ortiz-Cordero; James Kiley; Qi Long Lu; Anne G Bang; Rita C R Perlingeiro
Journal:  Cell Rep       Date:  2021-07-13       Impact factor: 9.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.